Hemady (Dexamethasone) Patent Expiration, LOE Window & CMS Spending

Hemady (Dexamethasone) by Dexcel Technologies: FDA Orange Book LOE 2037-12-18, 15 AB generics, $130K 2024 CMS Part D & Medicaid spend, and $2,740 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorDexcel Technologies
FDA Application & PathwayN211379 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2037-12-18
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors15
2024 CMS Total Public Spend$130K
2024 Medicare Part D Spend$120K
2024 Medicaid Spend$10K
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($2,740 intro WAC)